drugset / Trial / NCT03578198
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase 2
Terminated
12 enrolled
Seoul National University Hospital
Gyeongsang National University Hospital · collabHallym University Medical Center · collabKyunghee University Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials
Timeline
- Start
- 2018-11-08
- Primary completion
- 2022-04-07
- Completion
- 2022-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MG4101 | Cell therapy | 3e+07 cells/kg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |